Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants made by its Compensation Committee on January 31, 2026. One new employee received options to purchase 6,600 shares at a per-share exercise price of $5.84 under the company’s 2025 Inducement Plan.
The options vest 25% after one year of service and the remaining 75% in 36 equal monthly installments, subject to continued employment. The Plan was adopted by the board on December 24, 2025.
Positive
- None.
Negative
- None.
News Market Reaction – CADL
In the Feb 3 session, CADL gained 0.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | R&D day announcement | Positive | -2.3% | Announcement of December 5 virtual R&D event covering pipeline and strategy. |
| Nov 13 | Q3 2025 earnings | Positive | -6.3% | Q3 results plus CAN‑2409 data, BLA timing, and funding into Q1 2027. |
| Nov 04 | Clinical data update | Positive | -1.7% | SITC 2025 presentations with positive CAN‑2409 trial and AI‑designed candidate data. |
| Nov 03 | Conference presentation | Positive | -3.0% | Jefferies Global Healthcare Conference appearance announcement and webcast details. |
| Oct 16 | Advisory board change | Positive | -9.3% | Addition of systems immunology expert to Research Advisory Board for lead programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including clinical and corporate updates, has often been followed by negative one-day price reactions despite generally constructive announcements.
Over the last few months, Candel issued several clinically and strategically focused updates, including Q3 2025 results with $87.0M cash and a $130M term loan, positive CAN‑2409 Phase 3 data, and CAN‑3110 survival data. It also highlighted upcoming R&D and conference events and a key advisory board appointment. Yet the stock saw negative 24‑hour moves after each of these announcements, indicating a pattern of weak near-term price responses to ostensibly positive or neutral news items.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
